HPV Nine-Valent Vaccine (Gardasil 9) is Contraindicated During Pregnancy
The 9-valent HPV vaccine should not be administered during pregnancy, though inadvertent exposure does not appear to cause harm and is not an indication for pregnancy termination. 1, 2
Current Contraindication Status
The FDA drug label explicitly states that "safety and effectiveness of GARDASIL 9 have not been established in pregnant women" 2. The most recent ACOG guidelines (2026) clearly list HPV vaccine as contraindicated during pregnancy in their maternal immunization table 1. However, the vaccine can be initiated while breastfeeding and postpartum 1.
What Happens with Inadvertent Exposure
Despite the contraindication, the safety data from inadvertent exposures are reassuring:
Pregnancy registry data (2014-2021): Among 70 prospectively enrolled pregnancies with known outcomes, there were 66 live births (95.7%), 3 miscarriages (4.3%), and 3 major birth defects (4.5%) 3. These rates are consistent with background population rates.
FDA label data: Analysis of 62 pregnancies exposed within 30 days of vaccination showed a 27.4% miscarriage rate (compared to 12.7% in controls receiving quadrivalent HPV vaccine), but 0% major birth defects among live births 2. A larger five-year registry of 1,640 pregnancies showed 6.8% miscarriage rate and 2.4% major birth defects—both within expected background rates 2.
VAERS surveillance: Among 82 pregnancy reports (2014-2017), most (73.2%) reported no adverse events, with only 3 spontaneous abortions (3.7%) 4.
Clinical Management Algorithm
If a patient is discovered to be pregnant:
- Stop the vaccination series immediately until after pregnancy completion
- Do not terminate the pregnancy based on inadvertent vaccine exposure
- Counsel the patient that available data are reassuring regarding pregnancy outcomes
- Encourage registry enrollment by calling 1-800-986-8999 2
- Resume vaccination postpartum or while breastfeeding 1
Before each vaccination dose:
- Screen for pregnancy with history and/or testing as appropriate
- Defer vaccination if pregnancy is detected 2
Important Caveats
The contraindication exists primarily because efficacy and safety have not been formally established in controlled trials during pregnancy—not because of demonstrated harm 2. The distinction is critical for counseling patients who were inadvertently exposed. Both patients and providers express significant uncertainty about HPV vaccine safety in pregnancy and desire more research before feeling comfortable with antepartum administration 5.
The vaccine can and should be offered immediately postpartum or during breastfeeding to complete the series and provide protection before subsequent pregnancies 1.